NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
More news: Health / Surgery
Written by / Agency / Source: General Electric Company
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

DiscGenics Engages CCRM and GE Healthcare to Support Scale-up Efforts for New Cell Therapy - New Cell Therapy Could Help Millions Suffering from Back Pain - DiscGenics.com / CCRM.ca / GEHealthcare.com
DiscGenics Engages CCRM and GE Healthcare to Support Scale-up Efforts for New Cell Therapy

 

NewswireToday - /newswire/ - Toronto, Ontario, Canada, 2018/05/30 - New Cell Therapy Could Help Millions Suffering from Back Pain - DiscGenics.com / CCRM.ca / GEHealthcare.com. NYSE: GE

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health / Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Degenerative disc disease (DDD) is one of the most common causes of chronic low back pain a condition that affects approximately 25 million adults in the U.S. alone[1]. Current treatments range from exercise, non-invasive physical therapy and pain medication, through to spinal surgery in severe cases. DiscGenics, a regenerative medicine company that develops therapies to alleviate pain and restore function in patients with degenerative diseases of the spine, has engaged with CCRM and GE Healthcare, leaders in developing and commercializing cell and gene therapy technologies, to support the Company’s efforts to scale and optimize manufacturing of its homologous, allogeneic (off-the-shelf), injectable cell therapy, which is referred to as IDCT.

Through the partnership, the CCRM and GE Healthcare team, working out of CCRM’s Toronto headquarters, are conducting process, assay, and media development for DiscGenics’ manufacturing process, which begins with isolating cells from donated intervertebral disc tissue and results in highly-specialized “Discogenic Cells” to address the complex environment of the degenerated disc. This approach enables DiscGenics to introduce restorative progenitor cells to the damaged disc and offers a therapeutic option for millions suffering from the debilitating effects of back pain.

“We recently initiated a Phase I/II trial of IDCT in patients with DDD, and in preparation for commercialization, we are committed to optimizing our in-house manufacturing capabilities and ensuring our processes comply with cGMP regulations,” says Flagg Flanagan, Chief Executive Officer and Chairman of the Board of Directors for DiscGenics. “The CCRM and GE Healthcare team is playing an integral role in these manufacturing initiatives by providing invaluable scale-up know-how and process development expertise, as well as allowing us to evaluate manufacturing equipment options.”

CCRM and GE Healthcare are conducting the work through their partnership with the Federal Economic Development Agency for Southern Ontario (FedDev Ontario) in the Centre for Advanced Therapeutic Cell Technologies (CATCT). The centre was established to accelerate the development and adoption of cell manufacturing technologies that improve patient access to novel regenerative medicine-based therapies. The projects are executed at CCRM, in CATCT’s 10,000 ft² (~930 m²) development facility in the MaRS Discovery District, next to Toronto’s world-leading hospitals and the University of Toronto.

“The DiscGenics project is an excellent case study of CATCT’s ability to successfully accelerate scale-up and process development,” says Michael May, President and CEO, CCRM. “This is yet another example of how CCRM and GE Healthcare are fulfilling their mission of supporting cell and gene therapy by industrializing cell manufacturing and delivering results that help customers develop better treatments for patients.”

“Manufacturers need to be able to duplicate product attributes at larger scale as they progress through clinical trials and into commercial phases, so it’s critical to develop scaled up manufacturing processes early on,” says Phil Vanek, GM of Cell and Gene Therapy Strategy at GE Healthcare Life Sciences. “DiscGenics was an early adopter of the process development capabilities we’ve built together with CCRM, and we look forward to continued collaborations.“

About DiscGenics
DiscGenics is a privately held, clinical stage regenerative medicine company focused on developing cell therapies that alleviate pain and restore function in patients with degenerative diseases of the spine. DiscGenics is harnessing the restorative potential of cells native to the intervertebral disc to develop what we hope will be a profound therapeutic option for millions suffering from the debilitating effects of back pain. Our first product candidate, IDCT, is a homologous, allogeneic, injectable cell therapy for the treatment of patients with degenerative disc disease (DDD).

About CCRM
CCRM (ccrm.ca), a Canadian not-for-profit organization funded by the Government of Canada, the Province of Ontario, and leading academic and industry partners, supports the development of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy. A network of researchers, leading companies, strategic investors and entrepreneurs, CCRM aims to accelerate the translation of scientific discovery into new companies and marketable products for patients, with specialized teams, funding, and infrastructure. CCRM is the commercialization partner of the Ontario Institute for Regenerative Medicine and the University of Toronto’s Medicine by Design. CCRM is hosted by the University of Toronto.

About GE Healthcare
Harnessing data and analytics across hardware, software and biotech, GE Healthcare (gehealthcare.com) is the $19 billion healthcare business of GE (NYSE: GE). As a leading provider of medical imaging equipment, with a track record of more than 100 years in the industry and more than 50,000 employees across 100 countries, we transform healthcare by delivering better outcomes for providers and patients.

[1] Nahin R, et al. “Estimates of Pain Prevalence and Severity in Adults: United States, 2012.” J of Pain. Aug 2015;16(8):769-780.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Health / Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: General Electric Company

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Health / Surgery articles,
CATCH Visitors via Your Competitors Announcements!


DiscGenics Engages CCRM and GE Healthcare to Support Scale-up Efforts for New Cell Therapy

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Rachel Eides - GE Healthcare Life Sciences 
281-409-1031 rachel.eides[.]ge.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any General Electric Company securities in any jurisdiction including any other companies listed or named in this release.

Health / Surgery via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From General Electric Company / Company Profile


Read Health / Surgery Most Recent Related Newswires:

Syapse Awarded 2021 Technology Innovation Leadership Award by Frost & Sullivan for Accelerating Real-world Care Delivery
Lumeon Commended by Frost & Sullivan for Enabling Digital Transformation in Healthcare
Payment Integrity Solutions Enable Healthcare Plans to Optimize Processes and Maximize Returns Finds Frost & Sullivan
Menopause to Become the Next Game-changer in the Global Femtech Solutions Industry by 2025 Finds Frost & Sullivan
Innovative MedTech Business Models Will Enable Cost-effective, Decentralized and Patient-centric Care Finds Frost & Sullivan
Data Monetization a Must for MedTech Industry to Evolve Toward Real-World Evidence and Precision Medicine Finds Frost & Sullivan
InterSystems Partners with Cognetivity on Ground-breaking AI Solution for Early Dementia Detection
Humimic Medical, Partners Team Up to Make A Difference in South Carolina COVID Battle
Adoption of HaH Model Surged Eight-fold with the Availability of Advanced Remote Monitoring and Digital Health Solutions Finds Frost & Sullivan
Major Innovation Announcement Planned, SC Life Sciences Conference Shatters Registration Record
South Carolina Life Sciences Conference Adds Top Executives from Microsoft, Alphabet, PhRMA
SC Life Sciences Conference to Feature BIO Global Executive February 16-17
20Lighter Announces Orthopedic Surgery Alliance
Calmerry Introduces Individual, Couples and Family Online Therapy with Licensed Professionals
CoverMyMeds Lauded by Frost & Sullivan for Seamlessly Connecting the Healthcare Network with its Industry-leading ePA Platform

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  RightITnow, Inc.





 
  ©2021 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)